Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06916806 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

A Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
72
Enrollment target
20
Study locations

NCT06916806 is a Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 72 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06916806, a Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. * Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1) or twice (Part 2). * Study visits will occur at: Screening, Days 1-4, 8, 15, 22, 30, 60, 90, 120, 150, and 180 in Part 1, Screening, Days 1-4, 8-11, 15, 22, 29, 43, 60, 90, 120, 150, and 180 in Part 2.

Conditions Studied

Rheumatoid Arthritis Systemic Lupus Erythematosus Idiopathic Inflammatory Myopathies

Interventions

  • DRUG AZD5492

Study Locations (20)

Other

  • Research Site - Beijing
  • Research Site - Shanghai
  • Research Site - Wuhan
  • Research Site - Bordeaux
  • Research Site - Montpellier
  • Research Site - Nancy
  • Research Site - Paris
  • Research Site - Strasbourg
  • Research Site - Toulouse
  • Research Site - Cologne
  • Research Site - Erlangen
  • Research Site - Magdeburg
  • Research Site - Bunkyō City

Alabama

  • Research Site - Anniston
  • Research Site - Birmingham

California

  • Research Site - La Jolla
  • Research Site - Sacramento

Iowa

  • Research Site - Iowa City

Ontario

  • Research Site - Hamilton

Quebec

  • Research Site - Sherbrooke

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2025-05-01
Est. Completion 2027-06-22
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06916806

The ClinicalTrials.gov registry entry for NCT06916806 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which AZD5492 is the first listed.

NCT06916806 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT06916806 about?

NCT06916806 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.". The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visit...

What is the current status of trial NCT06916806?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-05-01. Estimated completion is 2027-06-22.

What conditions does trial NCT06916806 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies.

What interventions are being tested in trial NCT06916806?

The interventions under investigation include: AZD5492 (DRUG).

Who is sponsoring clinical trial NCT06916806?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06916806 being conducted?

This trial has 20 study locations across Alabama, California, Iowa, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Systemic Lupus Erythematosus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.